Indian pharma should explore opportunities in potential markets
UBM India recently hosted the 5th edition of PharmaLytica 2018 in Hyderabad at the HITEX Exhibition Centre, with BioSpectrum serving as the conference partner. The two day event was inaugurated by Dr Preeti Meena, Director, Drugs Control Administration, Hyderabad along with Uday Bhaskar Reddy, Director General, Pharmaceuticals Export Promotion Council (PHARMEXCIL), Dr Appaji PV, Director General Emeritus, PHARMEXCIL, Avinash Talwar, Director & Head, Global Sourcing (Strategic & Plant) Dr. Reddy’s Laboratories Ltd, Dr R B Smarta, Managing Director, Interlink Marketing Consultancy, Yogesh Mudras, Managing Director, UBM India and Rahul Deshpande, Group Director, UBM India amidst a gathering of industry experts and government officials.
PharmaLytica event over the years has been providing a platform to the pharmaceutical community to procure the current industry trends, innovations and conduct business with Analytical, Laboratory, Machinery, Packaging and other allied Industries. The expo is well supported by associations, including Pharmexcil, Confederation of Indian Pharmaceutical Industry (CiPi) and Indian Drug Manufacturers’ Association (IDMA).
At the inaugural session, Uday Bhaskar Reddy, DG, PHARMEXCIL said, “In FY 2017-18, Indian Pharma exports grew to $17.26 billion. One of the key development to notice is, despite 8 per cent negative growth witnessed in the US market, we still grew positive by 2.92 per cent. There are potential markets to explore like China, South Africa and Commonwealth of Independent States (CIS) markets and even if negative growth continues in the US market, the Indian pharma companies should be confident and focus on growth and explore opportunities in the potential markets.”
Over the two days, experts from organisations such as Dr. Reddy’s Laboratory, Novartis Healthcare, Deloitte, Pfizer Healthcare, USP India, Aztec India, Apex Lab deliberated over the various trends and issues related to quality assurance technologies, maintenance of quality culture and regulatory compliance standards within the Indian pharmaceutical sector.
“The availability of good quality drugs is of extreme importance. Today, the Indian population is suffering from a large number diseases such as hypertension, diabetes etc. We need to make sure that our drugs are free from impurities and toxicity. Good manufacturing set ups are required in the pharmaceutical production facilities to ensure the correct quality of the products. We are accountable for using appropriate machinery, equipment and other inputs in order to ensure quality production. We also need to maintain data integrity which is a very critical issue of deviation. Wherever required, global standards should be implemented even if it comes in return with high pricing”, said Dr Appaji PV, DG Emeritus, PHARMEXCIL, during the first session of the two-day event. PharmaLytica witnessed a participation from over 150 exhibitors from across the country-Kirloskar, Standard Group of Companies, Borosil Glass Works, Bry-Air Asia, Rotomark Innovations, Control Print, Gandhi Automation, Leistung Engineering among many others.
L-R- Rahul Deshpande, Group Director, UBM India; Yogesh Mudras, Managing Director, UBM India; Uday Bhaskar Reddy, Director General, Pharmaceuticals Export Promotion Council (PHARMEXCIL); Dr P V Appaji, Director General Emeritus, Pharmaceuticals Export Promotion Council (PHARMEXCIL); Avinash Talwar, Director & Head, Global Sourcing (Strategic & Plant)Dr. Reddy’s Laboratories Ltd;Dr.R B Smarta, MD, Interlink Marketing Consultancy, Milind Kokje, Chief Editor, BioSpectrum at the inauguration ceremony of the 5th Edition of PharmaLytica at the Hitex Exhibition Centre, Hyderabad, India.